# OSENSUS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/osensus

- Industry: Healthcare Specialists
- Headquarters: Hangzhou, China
- Latest round: Seed (Jun 17, 2026)
- Investors on record: 1

## About

Based in Hangzhou, China, and founded in 2025, To Shu Intelligent Technology (Hangzhou) Co., Ltd., trading as OSENSUS, focuses on the field of AI-driven precision oncology diagnosis and treatment. The company boasts a top-tier core team, comprised of experts from Harvard Medical School, prestigious universities in Europe and America, and senior industry professionals. In June 2026, OSENSUS raised a Seed funding from Goldport Capital.

Leveraging core technologies such as proteomics + multi-omics fusion and its self-developed small-sample AI architecture, it has created the AIMPO treatment solution, filling a gap in the domestic AI-driven cancer treatment market. The company collaborates with multiple top-tier hospitals both domestically and internationally for clinical trials, and is simultaneously advancing medical device registration, clinical trials, and new drug CRO business. 

The company generates revenue by doing R&D, providing AI-driven precision oncology diagnosis and treatment and related services.
 
The Seed funding raised in June 2026 will be strategically allocated to multi-center prospective clinical trials, core underlying algorithm iteration, large-scale multimodal model training, market access and commercialization, and the construction of high-throughput proteomics experimental infrastructure.

## Funding rounds

- Seed, Jun 17, 2026 — Goldport Capital

## Investors

- Goldport Capital (https://capitalatlas.ai/funds/goldport-capital) — Seed